Stronger Sell Today CATB ranks #2510 as SELL CANDIDATE. Weaker Sell
Today CATB ranks #2510 as SELL CANDIDATE.

CATB stock Catabasis Pharmaceuticals

CATB stock
Catabasis Pharmaceuticals

Tue 11'th Dec 2018

PERIOD 2018-09-12 - 2018-12-11
CHANGE 2.45%
VOLUME
Sell
TREND
Sell

MV LONG
Sell

MV SHORT
Sell

PIVOT
Buy

MACD
Buy
Request Prediction
0.00%
Predict

Catabasis Pharmaceuticals Stock Analysis

Technical stock analysis for Tue 11'th Dec 2018

Sell candidate since 2018-12-04 Loss -1.62%
Shorts n/a
Cash n/a
Loans n/a
Beta 0.72
ROA -74.68

Catabasis Pharmaceuticals gained 2.45% in the last trading day, rising from $0.60 to $0.61 , and has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. The price has risen in 7 of the last 10 days and is up by 6.02% over the past 2 weeks. Volume fell in the last day by -173 888 shares, and in total, 244 285 shares bought and sold for approximately $150 211.00. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.

Trend

Catabasis Pharmaceuticals lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -27.36% during the next 3 months and, with 90% probability hold a price between $0.36 and $0.48 at the end of this period.

Click here for today's Top 5 Trending Companies

Signals

A buy signal was issued from a pivot bottom point on Thursday December 06, 2018, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Catabasis Pharmaceuticals holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $0.62 and $0.64. A break-up above any of these levels will issue buy signals. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.

Access today's Top 5 Golden Star Companies

Relative Strength Index (RSI)

RSI14 is 53 and the stock is currently not being overbought or oversold

Access full RSI 14 and RSI 21 lists

Support & Resistance

Catabasis Pharmaceuticals finds support from accumulated volume at $0.60.

Support: $0.60 Price: $0.61 Resistance: $0.64

Risk

This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.06 between high and low, or 10.53%. For the last week the stock has had a daily average volatility of 10.20%.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

Overall risk:

Very Low Low Medium High Very High

Evaluation

Catabasis Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Stronger Sell Today CATB ranks #2510 as SELL CANDIDATE. Weaker Sell
Today CATB ranks #2510 as SELL CANDIDATE.